1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

US FDA Adds New Faces To Vaccines Adcomm For Pfizer/BioNTech COVID-19 Review

 
• By Derrick Gingery

The Vaccines and Related Biological Products Advisory Committee will have five more members than were present for the 22 October meeting on coronavirus vaccine development and approval issues.

FDA Advisory Committee Feature image
The 10 December Vaccines and Related Biological Products Advisory Committee meeting runs from 9 a.m. to 5:15 p.m. • Source: Pink Sheet illustration

The US Food and Drug Administration will hear from several new voices during what is scheduled to be an unconventional Vaccines and Related Biological Products Advisory Committee on the Pfizer Inc./BioNTech SE coronavirus vaccine candidate. The product is proposed for people age 16 and older.

FDA officials expanded the size of the VRBPAC for the 10 December meeting, according to the

More Pink Sheet Coverage Of The Pfizer/BioNTech COVID-19 Vaccine Advisory Committee Meeting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

AMR-Targeting Drug Secures EMA PRIME Designation

 
• By Neena Brizmohun

Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.

Global Pharma Guidance Tracker - March 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman

Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.